Inventor · disambiguated record
William Olson
Also filed as: OLSON WILLIAM · OLSON WILLIAM C
87 granted patents·58 pending applications·1,377 citations·filing 1989–2025
99Inventor score
Top patents by PatentIndex Score
145 records- 0197US11760775B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2020·Granted Sep 19, 2023·5 cites·9 claims
- 0297US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 0397US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 0497US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 0596US11530255B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2020·Granted Dec 20, 2022·3 cites·18 claims
- 0696US11511001B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2020·Granted Nov 29, 2022·3 cites·7 claims
- 0796US10730944B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 4, 2020·30 cites·56 claims
- 0896US10711032B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2017·Granted Jul 14, 2020·10 cites·33 claims
- 0996US9771414B2Human antibodies to ebola virus glycoproteinREGENERON PHARMA·Filed 2016·Granted Sep 26, 2017·18 cites·32 claims
- 1096US8470330B2PSMA antibodies and uses thereofMADDON PAUL J·Filed 2010·Granted Jun 25, 2013·50 cites·31 claims
- 1195US12077587B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 3, 2024·2 cites·19 claims
- 1295US11896682B2Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Feb 13, 2024·3 cites·47 claims
- 1395US11525001B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Dec 13, 2022·5 cites·56 claims
- 1495US10633434B2Anti-C5 antibodiesREGENERON PHARMA·Filed 2017·Granted Apr 28, 2020·20 cites·18 claims
- 1595US8114965B2Compositions of PSMA antibodiesMADDON PAUL J·Filed 2007·Granted Feb 14, 2012·52 cites·47 claims
- 1695US7592014B2Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2005·Granted Sep 22, 2009·34 cites·17 claims
- 1794US12053534B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·2 cites·26 claims
- 1894US11491237B2Cyclodextrin protein drug conjugatesREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·6 cites·59 claims
- 1994US10501526B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2018·Granted Dec 10, 2019·11 cites·13 claims
- 2094US7060273B2Methods for inhibiting HIV-1 infectionPROGENICS PHARM INC·Filed 2002·Granted Jun 13, 2006·32 cites·24 claims
- 2194US6692745B2Compositions and methods for inhibition of HIV-1 infectionPROGENICS PHARM INC·Filed 2000·Granted Feb 17, 2004·37 cites·15 claims
- 2293US11732030B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·51 claims
- 2393US10081670B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2017·Granted Sep 25, 2018·10 cites·13 claims
- 2493US7939083B2Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomainPROGENICS PHARM INC·Filed 2007·Granted May 10, 2011·55 cites·21 claims
- 2593US7122185B2Anti-CCR5 antibodyPDL BIOPHARMA INC·Filed 2003·Granted Oct 17, 2006·50 cites·75 claims
- 2693US6710173B1Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2000·Granted Mar 23, 2004·36 cites·30 claims
- 2792US10421804B2Anti-Zika virus antibodies and methods of useREGENERON PHARMA·Filed 2017·Granted Sep 24, 2019·11 cites·24 claims
- 2892US9695248B2PSMA antibodies and uses thereofMADDON PAUL J·Filed 2012·Granted Jul 4, 2017·9 cites·31 claims
- 2992US7666419B2Anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2006·Granted Feb 23, 2010·14 cites·36 claims
- 3092US6548636B2Sulfated CCR5 peptides for HIV-1 infectionPROGENICS PHARM INC·Filed 2001·Granted Apr 15, 2003·54 cites·4 claims
- 3192US6344545B1Method for preventing HIV-1 infection of CD4+ cellsPROGENICS PHARM INC·Filed 1997·Granted Feb 5, 2002·91 cites·6 claims
- 3291US11787867B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Oct 17, 2023·2 cites·24 claims
- 3391US10905784B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·9 cites·24 claims
- 3491US10829544B2Human antibodies to Ebola virus glycoproteinREGENERON PHARMA·Filed 2019·Granted Nov 10, 2020·2 cites·20 claims
- 3591US10736976B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·7 cites·6 claims
- 3691US9242012B2Methods for killing PSMA-expressing, taxane-resistant cancer cellsMA DANGSHE·Filed 2011·Granted Jan 26, 2016·34 cites·32 claims
- 3791US7022324B2Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2001·Granted Apr 4, 2006·31 cites·20 claims
- 3890US11117955B2Anti-Zika virus antibodies and methods of useREGENERON PHARMA·Filed 2019·Granted Sep 14, 2021·4 cites·18 claims
- 3990US10806780B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 20, 2020·4 cites·17 claims
- 4090US7138119B2Compositions and methods for inhibition of HIV-1 infectionPROGENICS PHARM INC·Filed 2001·Granted Nov 21, 2006·24 cites·15 claims
- 4189US8986697B2Antibodies for the treatment of Clostridium difficile-associated infection and diseaseMA DANGSHE·Filed 2011·Granted Mar 24, 2015·23 cites·24 claims
- 4289US7850971B2PSMA antibodies and protein multimersPSMA DEV COMPANY LLC·Filed 2003·Granted Dec 14, 2010·42 cites·27 claims
- 4389US6908734B2Sulfated CCR5 peptides for HIV-1 infectionAARON DIAMOND AIDS RES CT·Filed 2002·Granted Jun 21, 2005·32 cites·12 claims
- 4488US8821877B2Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonistOLSON WILLIAM C·Filed 2010·Granted Sep 2, 2014·10 cites·19 claims
- 4587US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 4686US12251440B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·16 claims
- 4786US6107019AMethod for preventing HIV-1 infection of CD4+ cellsPROGENICS PHARM INC·Filed 1997·Granted Aug 22, 2000·78 cites·12 claims
- 4885US12377159B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2023·Granted Aug 5, 2025·0 cites·23 claims
- 4985US10844137B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Nov 24, 2020·2 cites·20 claims
- 5084US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
Showing the top 50 of 145 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when William Olson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →